S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
3rd Massive Dollar Upheaval Has Started (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
3rd Massive Dollar Upheaval Has Started (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
3rd Massive Dollar Upheaval Has Started (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
3rd Massive Dollar Upheaval Has Started (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
3rd Massive Dollar Upheaval Has Started (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
3rd Massive Dollar Upheaval Has Started (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
3rd Massive Dollar Upheaval Has Started (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
3rd Massive Dollar Upheaval Has Started (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:CLSD

Clearside Biomedical - CLSD Stock Forecast, Price & News

$1.59
+0.04 (+2.58%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.56
$1.61
50-Day Range
$1.30
$1.83
52-Week Range
$1.26
$7.73
Volume
103,176 shs
Average Volume
549,597 shs
Market Capitalization
$95.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Clearside Biomedical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
403.1% Upside
$8.00 Price Target
Short Interest
Healthy
0.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Clearside Biomedical in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

211th out of 1,117 stocks

Pharmaceutical Preparations Industry

96th out of 550 stocks

CLSD stock logo

About Clearside Biomedical (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. StockNews.com upgraded Clearside Biomedical from a "hold" rating to a "buy" rating in a research note on Wednesday. HC Wainwright decreased their price target on Clearside Biomedical from $10.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, TheStreet cut Clearside Biomedical from a "c" rating to a "d+" rating in a report on Wednesday, May 11th. Four investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $8.00.

Clearside Biomedical Trading Up 2.6 %

Shares of CLSD Stock traded up $0.04 during trading hours on Friday, reaching $1.59. 103,176 shares of the company's stock were exchanged, compared to its average volume of 549,597. The stock's 50 day moving average is $1.55 and its 200-day moving average is $1.71. The company has a market cap of $95.64 million, a price-to-earnings ratio of -53.00 and a beta of 1.90. Clearside Biomedical has a fifty-two week low of $1.26 and a fifty-two week high of $7.73.

Clearside Biomedical (NASDAQ:CLSD - Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). Clearside Biomedical had a negative net margin of 5.54% and a negative return on equity of 5.60%. During the same period last year, the business earned ($0.11) EPS. Equities analysts anticipate that Clearside Biomedical will post -0.51 EPS for the current year.

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Stock News Headlines

Clearside Biomedical Q1 2022 Earnings Preview
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Company Calendar

Last Earnings
8/09/2022
Today
8/13/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSD
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+403.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$380,000.00
Pretax Margin
0.28%

Debt

Sales & Book Value

Annual Sales
$29.58 million
Cash Flow
$0.01 per share
Book Value
$0.64 per share

Miscellaneous

Free Float
52,932,000
Market Cap
$95.64 million
Optionable
Optionable
Beta
1.90














CLSD Stock - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price forecast for 2022?

3 brokerages have issued 12-month target prices for Clearside Biomedical's shares. Their CLSD share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 396.9% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2022?

Clearside Biomedical's stock was trading at $2.75 at the beginning of 2022. Since then, CLSD stock has decreased by 41.5% and is now trading at $1.61.
View the best growth stocks for 2022 here
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CLSD earnings forecast
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) released its earnings results on Tuesday, August, 9th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). Clearside Biomedical had a negative trailing twelve-month return on equity of 5.60% and a negative net margin of 5.54%. During the same quarter in the previous year, the firm earned ($0.11) earnings per share.

What other stocks do shareholders of Clearside Biomedical own?

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Carmignac Gestion (3.97%), Assenagon Asset Management S.A. (1.26%), Franklin Resources Inc. (0.13%), Synovus Financial Corp (0.11%), Connor Clark & Lunn Investment Management Ltd. (0.08%) and Mackenzie Financial Corp (0.06%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.61.

How much money does Clearside Biomedical make?

Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $96.84 million and generates $29.58 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033.

This page (NASDAQ:CLSD) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.